January 24, 2020 / 6:27 AM / a month ago

BRIEF-Swiss Regulator Grants Additional Approval For Roche's Antibody-Drug Kadcyla

Jan 24 (Reuters) - Roche Holding AG:

* ROCHE'S KADCYLA APPROVED FOR A NEW INDICATION IN EARLY HER2-POSITIVE BREAST CANCER IN SWITZERLAND

* SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC) HAS GRANTED ADDITIONAL APPROVAL FOR KADCYLA (TRASTUZUMAB EMTANSINE)

* ADDITIONAL APPROVAL OF KADCYLA IS BASED ON THE PHASE III KATHERINE STUDY, IN WHICH PATIENTS WITH AN EARLY FORM OF HER2-POSITIVE BREAST CANCER WHO WERE TREATED WITH KADCYLA HAD A 50% REDUCED RISK OF RELAPSE OR DEATH COMPARED TO STANDARD THERAPY Source text for Eikon: [tinyurl.com/rwzvbl2] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below